Susquehanna International Group
CCCC icon

Susquehanna International Group’s C4 Therapeutics CCCC Stock Holding History

Susquehanna International Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Buy
107,600
+39,300
+58% +$92.5K ﹤0.01% 10989
2025
Q4 		$130K Buy
68,300
+7,200
+12% +$17.1K ﹤0.01% 11284
2025
Q3 		$136K Buy
61,100
+45,900
+302% +$110K ﹤0.01% 11360
2025
Q2 		$21.7K Sell
15,200
-3,600
-19% -$5.24K ﹤0.01% 12314
2025
Q1 		$30.1K Buy
18,800
+900
+5% +$2.68K ﹤0.01% 12011
2024
Q4 		$64.4K Sell
17,900
-169,700
-90% -$844K ﹤0.01% 11575
2024
Q3 		$1.07M Sell
187,600
-73,300
-28% -$441K ﹤0.01% 6636
2024
Q2 		$1.21M Sell
260,900
-105,700
-29% -$630K ﹤0.01% 6137
2024
Q1 		$3M Sell
366,600
-24,300
-6% -$188K ﹤0.01% 4520
2023
Q4 		$2.21M Buy
+390,900
New +$891K ﹤0.01% 5149
2023
Q1 		– Sell
-18,900
Closed -$112K – 12626
2022
Q4 		$112K Buy
18,900
+6,400
+51% +$53.1K ﹤0.01% 10858
2022
Q3 		$110K Sell
12,500
-15,100
-55% -$157K ﹤0.01% 11612
2022
Q2 		$208K Sell
27,600
-8,500
-24% -$74.8K ﹤0.01% 10530
2022
Q1 		$876K Buy
36,100
+18,900
+110% +$459K ﹤0.01% 7468
2021
Q4 		$554K Sell
17,200
-79,300
-82% -$3.14M ﹤0.01% 8906
2021
Q3 		$4.31M Buy
96,500
+67,600
+234% +$2.89M ﹤0.01% 4226
2021
Q2 		$1.09M Buy
+28,900
New +$1.04M ﹤0.01% 7519

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's CCCC Position: Q1 2026 in Review

Susquehanna International Group reduced its C4 Therapeutics (CCCC) stake by 28% in Q1 2026, selling an estimated $1.15M and leaving 1,286,840 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #5024.

Susquehanna International Group first reported a position in CCCC in Q1 2021 and has held it in 20 quarters since. The position peaked at $5.66M in Q4 2023. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Susquehanna International Group held 1,286,840 shares of C4 Therapeutics worth $3.38M as of Q1 2026.
  • Susquehanna International Group sold 488,943 C4 Therapeutics shares in Q1 2026, an estimated $1.15M.
  • C4 Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5024 holding.
  • Susquehanna International Group first reported a position in C4 Therapeutics in Q1 2021 and has held it in 20 quarters since.
  • Susquehanna International Group's C4 Therapeutics position peaked at $5.66M in Q4 2023.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.